Artemether sublingual - LondonPharma

Drug Profile

Artemether sublingual - LondonPharma

Alternative Names: Artemether sublingual spray; ArTiMist; LON 002

Latest Information Update: 06 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ProtoPharma
  • Developer LondonPharma; ProtoPharma
  • Class Anthelmintics; Antifungals; Antimalarials; Antiprotozoals; Artemisinins; Fluorenes; Skin disorder therapies; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Carrier protein inhibitors; Mitochondrial protein inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Falciparum malaria
  • Phase I/II Solid tumours
  • Preclinical Cancer

Most Recent Events

  • 06 Aug 2015 Malaria Research Company is still in the process of preparing the regulatory dossier to support filings for Falciparum malaria in Rwanda, Ghana and Burkina Faso
  • 19 Dec 2014 Preclinical trials in Cancer in United Kingdom (Sublingual)
  • 01 Dec 2014 Phase-Ib clinical trials in Solid tumours in Africa (Sublingual) before December 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top